‘Immediately Practice-Changing’ Trial in Small Cell Lung Cancer

By News Health
3 months Ago

(MedPage Today) — CHICAGO — The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment of small cell lung cancer (SCLC), a practice-changing phase III trial showed.
In patients whose…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115891

Author :

Publish date : 2025-06-03 21:16:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Early Switch to Oral Antibiotics Effective in Endocarditis

Does Combination Therapy Increase Infection Risk in PsA?

Vitiligo Tied to Alopecia, RA, Other Autoimmune Diseases

Can CRISPR Help NK Cells Fight Cancer?

‘Forever Chemicals’ Curb Bariatric Surgery Success in Teens

Rapid Care Access Improves Outcomes in HIV